EA023713B1 - Производные фталазинонпирролопиримидинкарбоксамида - Google Patents
Производные фталазинонпирролопиримидинкарбоксамида Download PDFInfo
- Publication number
- EA023713B1 EA023713B1 EA201400001A EA201400001A EA023713B1 EA 023713 B1 EA023713 B1 EA 023713B1 EA 201400001 A EA201400001 A EA 201400001A EA 201400001 A EA201400001 A EA 201400001A EA 023713 B1 EA023713 B1 EA 023713B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- oxo
- piperidin
- cyclopropylmethoxy
- carboxamide
- dimethoxyphenyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract 34
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims abstract 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims abstract 2
- 239000003112 inhibitor Substances 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- -1 AADT-fluoroalkyl Chemical group 0.000 claims 171
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 121
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 119
- 229910052739 hydrogen Inorganic materials 0.000 claims 30
- 239000001257 hydrogen Substances 0.000 claims 30
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 30
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 22
- 125000001153 fluoro group Chemical group F* 0.000 claims 19
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 18
- 125000003545 alkoxy group Chemical group 0.000 claims 16
- 229910052731 fluorine Inorganic materials 0.000 claims 13
- 239000011737 fluorine Substances 0.000 claims 13
- PAWALTXRSMCTAC-ODTHDHSBSA-N (2S)-2-[[(2R)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]-3-sulfanylpropanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-sulfanylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-sulfanylpropanoyl]amino]-3-(1H-imidazol-5-yl)propanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](Cc1c[nH]cn1)C(O)=O PAWALTXRSMCTAC-ODTHDHSBSA-N 0.000 claims 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 12
- 150000002431 hydrogen Chemical class 0.000 claims 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 10
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 9
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 8
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 8
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 7
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 claims 7
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 7
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 claims 7
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims 7
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 7
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 5
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 5
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 150000001721 carbon Chemical group 0.000 claims 5
- 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 claims 5
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 5
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 claims 5
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims 5
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 claims 5
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 claims 5
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims 4
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 3
- 125000001246 bromo group Chemical group Br* 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 3
- 125000003003 spiro group Chemical group 0.000 claims 3
- KZKRRZFCAYOXQE-UHFFFAOYSA-N 1$l^{2}-azinane Chemical group C1CC[N]CC1 KZKRRZFCAYOXQE-UHFFFAOYSA-N 0.000 claims 2
- LOEIRDBRYBHAJB-UHFFFAOYSA-N 4,5,6,7-tetrabromo-1h-benzimidazole Chemical compound BrC1=C(Br)C(Br)=C2NC=NC2=C1Br LOEIRDBRYBHAJB-UHFFFAOYSA-N 0.000 claims 2
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims 2
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 2
- 208000030090 Acute Disease Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000014085 Chronic respiratory disease Diseases 0.000 claims 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims 2
- ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 150000003857 carboxamides Chemical class 0.000 claims 2
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims 2
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 claims 1
- 102000003834 Histamine H1 Receptors Human genes 0.000 claims 1
- 108090000110 Histamine H1 Receptors Proteins 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims 1
- 102000004316 Oxidoreductases Human genes 0.000 claims 1
- 108090000854 Oxidoreductases Proteins 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000005530 alkylenedioxy group Chemical group 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 229940082657 digitalis glycosides Drugs 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 1
- 239000003119 guanylate cyclase activator Substances 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims 1
- 230000008520 organization Effects 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 229960003073 pirfenidone Drugs 0.000 claims 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000001294 propane Substances 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 229960004617 sapropterin Drugs 0.000 claims 1
- 239000010802 sludge Substances 0.000 claims 1
- 239000000021 stimulant Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- NRHFWOJROOQKBK-UHFFFAOYSA-N triphenyltin;hydrate Chemical compound O.C1=CC=CC=C1[Sn](C=1C=CC=CC=1)C1=CC=CC=C1 NRHFWOJROOQKBK-UHFFFAOYSA-N 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- ZYKSLMIKRCOCDC-UHFFFAOYSA-N N1C(C(=O)N)=NC=C2N=CC=C21 Chemical compound N1C(C(=O)N)=NC=C2N=CC=C21 ZYKSLMIKRCOCDC-UHFFFAOYSA-N 0.000 description 1
- IJAPPYDYQCXOEF-UHFFFAOYSA-N phthalazin-1(2H)-one Chemical class C1=CC=C2C(=O)NN=CC2=C1 IJAPPYDYQCXOEF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11170440 | 2011-06-17 | ||
| PCT/EP2012/061084 WO2012171900A1 (en) | 2011-06-17 | 2012-06-12 | Novel phthalazinone-pyrrolopyrimidinecarboxamide derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201400001A1 EA201400001A1 (ru) | 2014-05-30 |
| EA023713B1 true EA023713B1 (ru) | 2016-07-29 |
Family
ID=44764312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201400001A EA023713B1 (ru) | 2011-06-17 | 2012-06-12 | Производные фталазинонпирролопиримидинкарбоксамида |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20140112945A1 (enExample) |
| EP (1) | EP2721030B1 (enExample) |
| JP (1) | JP5980318B2 (enExample) |
| KR (1) | KR20140037195A (enExample) |
| CN (1) | CN103582644B (enExample) |
| AR (1) | AR086915A1 (enExample) |
| AU (1) | AU2012269133A1 (enExample) |
| BR (1) | BR112013031791A2 (enExample) |
| CA (1) | CA2837248A1 (enExample) |
| CL (1) | CL2013003556A1 (enExample) |
| CO (1) | CO6852074A2 (enExample) |
| CR (1) | CR20130656A (enExample) |
| DO (1) | DOP2013000298A (enExample) |
| EA (1) | EA023713B1 (enExample) |
| EC (1) | ECSP13013076A (enExample) |
| ES (1) | ES2564882T3 (enExample) |
| MA (1) | MA35269B1 (enExample) |
| MX (1) | MX2013014888A (enExample) |
| PE (1) | PE20140648A1 (enExample) |
| PH (1) | PH12013502546A1 (enExample) |
| TN (1) | TN2013000439A1 (enExample) |
| WO (1) | WO2012171900A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10668120B2 (en) | 2015-04-09 | 2020-06-02 | Galderma Sa | Antibacterial indigo naturalis or indigo-producing plant extract and use thereof |
| EP3215169A1 (en) * | 2015-04-09 | 2017-09-13 | Galderma S.A. | Treatment of atopic dermatitis with indigo naturalis or indigo producing plant extract |
| SI3209313T1 (sl) | 2015-04-09 | 2019-03-29 | Galderma Sa | Izvleček iz indigo naturalis in postopek za njegovo pripravo |
| BR112017021190B1 (pt) | 2015-04-09 | 2021-12-21 | Galderma Sa. | Uso de uma composição farmacêutica que compreende um extrato de indigo naturalis |
| WO2022006470A1 (en) | 2020-07-01 | 2022-01-06 | Vanderbilt University | Methods of treatment for a kidney disease |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004018451A1 (en) * | 2002-08-10 | 2004-03-04 | Altana Pharma Ag | Pyridazinone-derivatives as pde4 inhibitors |
| WO2011023693A1 (en) * | 2009-08-26 | 2011-03-03 | Nycomed Gmbh | Methylpyrrolopyrimidinecarboxamides |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8828477D0 (en) | 1988-12-06 | 1989-01-05 | Riker Laboratories Inc | Medical aerosol formulations |
| DE69012458T3 (de) | 1989-05-31 | 2000-01-20 | Fisons Plc, Ipswich | Medikament und Inhalationsvorrichtung dafür. |
| GB8921222D0 (en) | 1989-09-20 | 1989-11-08 | Riker Laboratories Inc | Medicinal aerosol formulations |
| IE67185B1 (en) | 1990-02-02 | 1996-03-06 | Fisons Plc | Propellant compositions |
| DE4003272A1 (de) | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen |
| JPH05505824A (ja) | 1990-03-23 | 1993-08-26 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | 所定投与量エアロゾル製剤の製造のための可溶性弗素界面活性剤の使用 |
| DE69105212T2 (de) | 1990-10-18 | 1995-03-23 | Minnesota Mining And Mfg. Co., Saint Paul, Minn. | Aerosolzubereitung, die beclometason 17,21-dipropionat enthält. |
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| IL104068A (en) | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant |
| GB9213874D0 (en) | 1992-06-30 | 1992-08-12 | Fisons Plc | Process to novel medicament form |
| GB9306703D0 (en) | 1993-03-31 | 1993-05-26 | Fisons Plc | Inhalation device |
| IL111194A (en) | 1993-10-08 | 1998-02-08 | Fisons Plc | Process for the production of medicament formulations |
| NZ336573A (en) * | 1997-01-15 | 2000-10-27 | Byk Gulden Lomberg Chem Fab | 4-Phenyl substituted phthalazin-1-one derivatives useful for treating airway disorders |
| ES2224628T3 (es) * | 1998-03-14 | 2005-03-01 | Altana Pharma Ag | Inhibidores de pde iii/iv a base de ftalazinonas. |
| AU749697B2 (en) | 1998-08-04 | 2002-07-04 | Jagotec Ag | Medicinal aerosol formulations |
| US6397838B1 (en) | 1998-12-23 | 2002-06-04 | Battelle Pulmonary Therapeutics, Inc. | Pulmonary aerosol delivery device and method |
| AU777167B2 (en) | 1999-04-23 | 2004-10-07 | Battelle Memorial Institute | Directionally controlled EHD aerosol sprayer |
| ATE336301T1 (de) | 1999-04-23 | 2006-09-15 | Ventaira Pharmaceuticals Inc | Elektrostatisches versprühen mit transfer- hoher masse |
| JP2003535850A (ja) * | 2000-06-05 | 2003-12-02 | アルタナ ファルマ アクチエンゲゼルシャフト | β−２−アドレナリン受容体として効果的な化合物並びにＰＤＥ４−インヒビター |
| JP5021149B2 (ja) | 2000-10-09 | 2012-09-05 | スリーエム イノベイティブ プロパティズ カンパニー | 医療用エアロゾル調合物 |
| JP4301812B2 (ja) * | 2001-02-15 | 2009-07-22 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｐｄｅ４インヒビターとしてのフタラインオン−ピペリジノ−誘導体 |
| HUP0303998A3 (en) * | 2001-04-25 | 2007-03-28 | Altana Pharma Ag | Phthalazinones derivatives and pharmaceutical compositions containing them |
| WO2004018449A1 (en) | 2002-08-10 | 2004-03-04 | Altana Pharma Ag | Piperidine-derivatives as pde4 inhibitors |
| BR0313330A (pt) | 2002-08-10 | 2005-06-14 | Altana Pharma Ag | Piperidina-ftalazonas substituìdas com pirrolidinadiona como inibidores de pde4 |
| JP2006515367A (ja) * | 2003-01-14 | 2006-05-25 | アルタナ ファルマ アクチエンゲゼルシャフト | リンパ系細胞腫瘍の治療のためのｐｄｅ４阻害剤 |
| DE602005005638T2 (de) | 2004-02-04 | 2009-05-14 | Nycomed Gmbh | 2-(piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-on-derivate als pde4-inhibitoren |
| EP1720854A1 (en) | 2004-02-04 | 2006-11-15 | Altana Pharma AG | Phthalzinone derivatives as pde4 inhibitors |
| AR070454A1 (es) * | 2008-02-27 | 2010-04-07 | Nycomed Gmbh | Pirrolopirimidincarboxamidas y composiciones farmaceuticas que las comprenden |
-
2012
- 2012-06-12 BR BR112013031791A patent/BR112013031791A2/pt not_active IP Right Cessation
- 2012-06-12 CN CN201280028413.XA patent/CN103582644B/zh not_active Expired - Fee Related
- 2012-06-12 EP EP12728453.7A patent/EP2721030B1/en active Active
- 2012-06-12 PH PH1/2013/502546A patent/PH12013502546A1/en unknown
- 2012-06-12 MX MX2013014888A patent/MX2013014888A/es not_active Application Discontinuation
- 2012-06-12 EA EA201400001A patent/EA023713B1/ru not_active IP Right Cessation
- 2012-06-12 CA CA2837248A patent/CA2837248A1/en not_active Abandoned
- 2012-06-12 JP JP2014515155A patent/JP5980318B2/ja not_active Expired - Fee Related
- 2012-06-12 AR ARP120102088A patent/AR086915A1/es unknown
- 2012-06-12 US US14/125,187 patent/US20140112945A1/en not_active Abandoned
- 2012-06-12 KR KR1020147000392A patent/KR20140037195A/ko not_active Withdrawn
- 2012-06-12 AU AU2012269133A patent/AU2012269133A1/en not_active Abandoned
- 2012-06-12 WO PCT/EP2012/061084 patent/WO2012171900A1/en not_active Ceased
- 2012-06-12 ES ES12728453.7T patent/ES2564882T3/es active Active
- 2012-06-12 PE PE2013002801A patent/PE20140648A1/es not_active Application Discontinuation
-
2013
- 2013-10-29 TN TNP2013000439A patent/TN2013000439A1/fr unknown
- 2013-12-11 DO DO2013000298A patent/DOP2013000298A/es unknown
- 2013-12-11 EC ECSP13013076 patent/ECSP13013076A/es unknown
- 2013-12-11 CL CL2013003556A patent/CL2013003556A1/es unknown
- 2013-12-13 CR CR20130656A patent/CR20130656A/es unknown
-
2014
- 2014-01-10 CO CO14004200A patent/CO6852074A2/es not_active Application Discontinuation
- 2014-01-16 MA MA36689A patent/MA35269B1/fr unknown
-
2015
- 2015-12-03 US US14/958,141 patent/US20160108049A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004018451A1 (en) * | 2002-08-10 | 2004-03-04 | Altana Pharma Ag | Pyridazinone-derivatives as pde4 inhibitors |
| WO2011023693A1 (en) * | 2009-08-26 | 2011-03-03 | Nycomed Gmbh | Methylpyrrolopyrimidinecarboxamides |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103582644A (zh) | 2014-02-12 |
| ECSP13013076A (es) | 2014-01-31 |
| CO6852074A2 (es) | 2014-01-30 |
| EP2721030A1 (en) | 2014-04-23 |
| ES2564882T3 (es) | 2016-03-29 |
| MX2013014888A (es) | 2014-02-27 |
| CA2837248A1 (en) | 2012-12-20 |
| DOP2013000298A (es) | 2014-03-31 |
| KR20140037195A (ko) | 2014-03-26 |
| CR20130656A (es) | 2014-02-18 |
| JP2014517021A (ja) | 2014-07-17 |
| US20140112945A1 (en) | 2014-04-24 |
| EP2721030B1 (en) | 2015-12-16 |
| WO2012171900A1 (en) | 2012-12-20 |
| EA201400001A1 (ru) | 2014-05-30 |
| PH12013502546A1 (en) | 2014-01-27 |
| CN103582644B (zh) | 2016-07-20 |
| TN2013000439A1 (en) | 2015-03-30 |
| PE20140648A1 (es) | 2014-05-30 |
| JP5980318B2 (ja) | 2016-08-31 |
| MA35269B1 (fr) | 2014-07-03 |
| AU2012269133A1 (en) | 2014-01-30 |
| BR112013031791A2 (pt) | 2017-01-31 |
| AR086915A1 (es) | 2014-01-29 |
| CL2013003556A1 (es) | 2014-06-13 |
| US20160108049A1 (en) | 2016-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019301628C1 (en) | Pyridine carboxamide compounds for inhibiting NaV1.8 | |
| EP3820860B1 (en) | Pyridazine compounds for inhibiting nav1.8 | |
| ES2536191T3 (es) | Derivados de sulfonamida | |
| ES2532356T3 (es) | N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje | |
| RU2018140092A (ru) | Новые пиразолпиримидиновые производные | |
| EA023713B1 (ru) | Производные фталазинонпирролопиримидинкарбоксамида | |
| RU2558141C2 (ru) | Гетероароматические и ароматические пиперазинилазетидиниламиды в качестве ингибиторов моноацилглицеринлипазы | |
| RU2012116207A (ru) | Производные индола в качестве модуляторов crac | |
| JP6294559B1 (ja) | Ｎ型カルシウムチャネル遮断剤としての置換ピラゾール | |
| RU2011143359A (ru) | Примидинил- и 1,3,5-триазинилбензимидазолсульфонамиды и их применение в терапии рака | |
| AR082888A1 (es) | Compuestos de piridina para la inhibicion de nampt | |
| WO2012004714A2 (en) | Chemical compounds | |
| JPWO2002088107A1 (ja) | ピラゾリル基を置換基として有する含窒素縮合環化合物およびその医薬組成物 | |
| JP4734119B2 (ja) | インダゾール化合物及びその医薬用途 | |
| RU2013104939A (ru) | Амиды антралиновой кислоты в комбинации с фунгицидами | |
| WO2014028800A1 (en) | Substituted pyrazoles as n-type calcium channel blockers | |
| DK3172212T3 (en) | Aldosterone synthase inhibitors. | |
| JP2011510055A5 (enExample) | ||
| CN109776537A (zh) | 作为wnt通路调节剂的嘌呤二酮 | |
| CA3005918A1 (en) | Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof | |
| RU2014107000A (ru) | Производные 3-гетероароиламинопропионовой кислоты и их применение в качестве лекарственных средств | |
| RU2019123319A (ru) | Пиразолопиримидины и способы их применения | |
| WO2011005052A2 (en) | Novel arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same | |
| JP2015524483A5 (enExample) | ||
| RU2019117958A (ru) | Производные индола, полезные в качестве ингибиторов диацилглицерид-о-ацилтрансферазы 2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC4A | Registration of transfer of a eurasian patent by assignment | ||
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |